Alogliptin versus voglibose in NAFLD patients with impaired glucose tolerance or type 2 diabetes mellitus.

Trial Profile

Alogliptin versus voglibose in NAFLD patients with impaired glucose tolerance or type 2 diabetes mellitus.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2013

At a glance

  • Drugs Alogliptin (Primary) ; Voglibose
  • Indications Glucose intolerance; Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Jul 2011 New trial record
    • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
    • 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top